Vanda Pharmaceuticals Inc. (LON:0LKB)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 220.65M +19.6% |
| Revenue (ttm) | 162.59M +6.0% |
| Net Income | -207.16M |
| EPS | -3.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,566 |
| Open | 5.000 |
| Previous Close | 4.920 |
| Day's Range | 4.870 - 5.050 |
| 52-Week Range | 4.170 - 10.240 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develop... [Read more]
Financial Performance
In 2025, Vanda Pharmaceuticals's revenue was $216.11 million, an increase of 8.72% compared to the previous year's $198.77 million. Losses were -$220.47 million, 1066.5% more than in 2024.
Financial numbers in USD Financial StatementsNews
Vanda Pharmaceuticals price target lowered to $12 from $17 at B. Riley
B. Riley lowered the firm’s price target on Vanda Pharmaceuticals (VNDA) to $12 from $17 and keeps a Buy rating on the shares. Vanda’s Q2 revenue miss was largely timing-related,…
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $21 and keeps a Buy rating on the shares. The company reported a revenue and earnings…
Vanda Pharmaceuticals Earnings Call Transcript: Q2 2026
Fanapt and NEREUS drove strong prescription growth, while BYSANTI's approval and upcoming launch, along with multiple late-stage clinical trial readouts, position the company for significant expansion. Revenues were flat year-over-year, with higher operating expenses and a larger net loss, but cash reserves are expected to fund operations through 2027.
Vanda Pharmaceuticals Earnings release: Q2 2026
Vanda Pharmaceuticals released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Vanda Pharmaceuticals Quarterly report: Q2 2026
Vanda Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 5, 2026.
Vanda Pharmaceuticals reports Q2 EPS ($1.04) vs. (46c) last year
Reports Q2 revenue $50.53M vs. $52.59M last year. “We are pleased with the continued strong growth of Fanapt and the enthusiastic early response to NEREUS as it becomes available to…
Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
16:03 EDT Vanda Pharmaceuticals (VNDA) sees FY26 revenue $240M-$290M, consensus $262.1M
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31% Full-year 2026 total revenue guidance of $240-$290 million Cash totaled $170.0 million as of June ...
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on...
Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab
Vanda Pharmaceuticals (VNDA) announced that the Committee for Orphan Medicinal Products at the European Medicines Agency has adopted a positive opinion recommending orphan drug designation for imsidol...
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has ...
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of...
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle...
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
The company states: “Vanda Pharmaceuticals (VNDA) announced that the FDA has granted Rare Pediatric Disease Designation to VCA-894A, Vanda’s investigational antisense oligonucleotide therapy for the t...
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designati...
Vanda Pharmaceuticals Transcript: AGM 2026
Directors were elected through 2029, executive compensation and an equity plan amendment were approved, and PricewaterhouseCoopers LLP was ratified as auditor. No shareholder questions were submitted during the meeting.
Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan
Vanda Pharmaceuticals (VNDA) announced that Japan’s Ministry of Health, Labour and Welfare has granted orphan drug designation to imsidolimab, a high-affinity humanized immunoglobulin G4 monoclonal an...
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designatio...
Vanda Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Revenue guidance for 2026 was raised to $240–$290 million, driven by new launches and strong Fanapt growth. BYSANTI and NEREUS are expected to be key contributors, with multiple late-stage pipeline readouts and a focus on funding commercial and R&D initiatives.
Vanda Pharmaceuticals Slides: Corporate presentation
Vanda Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vanda Pharmaceuticals (VNDA) to $21 from $24 and keeps a Buy rating on the shares. The firm cites the company’s higher outer-year…
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
WASHINGTON, May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May 2026: ...
Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
Reports Q1 revenue $51.72B, consensus $52.9M. “Vanda delivered strong commercial execution in the first quarter, highlighted by 26% growth in Fanapt sales, the groundbreaking U.S. launch of NEREUS wit...
Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
2026 revenue consensus $258.2M.
Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 26% Fanapt sales growth, NEREUS launch, and BYSANTI FDA approval. Revenue guidance was raised to $240M–$290M, with strong pipeline progress and continued investment in commercial infrastructure.